Age-related macular degeneration 12

Common Name(s)

Age-related macular degeneration 12

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Age-related macular degeneration 12" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Age-related macular degeneration 12" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Age-related macular degeneration 12" returned 13 free, full-text research articles on human participants. First 3 results:

Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular Degeneration.
 

Author(s): Carl D Regillo, Brandon G Busbee, Allen C Ho, Beiying Ding, Zdenka Haskova

Journal: Am. J. Ophthalmol.. 2015 Nov;160(5):1014-1023.e2.

 

To identify baseline characteristics predictive of visual acuity (VA) outcomes at month 12 (M12) and treatment frequency in the first 12 months of the phase III HARBOR study.

Last Updated: 25 Nov 2015

Go To URL
Routine versus As-Needed Bevacizumab with 12-Weekly Assessment Intervals for Neovascular Age-Related Macular Degeneration: 92-Week Results of the GMAN Trial.
 

Author(s): Sajjad Mahmood, Stephen A Roberts, Tariq M Aslam, Jeremy Parkes, Kate Barugh, Paul N Bishop,

Journal: Ophthalmology. 2015 Jul;122(7):1348-55.

 

To evaluate the efficacy and safety of intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA) in patients with neovascular age-related macular degeneration (nAMD) using 2 different treatment regimens in which patients were assessed clinically at up to 12-week intervals.

Last Updated: 26 Jun 2015

Go To URL
Morphological changes in spectral domain optical coherence tomography guided bevacizumab injections in wet age-related macular degeneration, 12-months results.
 

Author(s): Janusz Michalewski, Jerzy Nawrocki, Bartosz Izdebski, Zofia Michalewska

Journal: Indian J Ophthalmol. 2014 May;62(5):554-60.

 

To describe retinal changes during Spectral Domain Optical Coherence Tomography (SD-OCT) guided bevacizumab treatment for neovascular age- related macular degeneration (AMD).

Last Updated: 2 Jun 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Age-related macular degeneration 12" returned 0 free, full-text review articles on human participants.

 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)
 

Status: Not yet recruiting

Condition Summary: Retinal Pigment Epithelial Detachment Secondary to Age-related Macular Degeneration

 

Last Updated: 19 May 2014

Go to URL
Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START
 

Status: Recruiting

Condition Summary: Neovascular Age-related Macular Degeneration of All Subtypes

 

Last Updated: 22 Oct 2014

Go to URL